The NightLife study — the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial
Author:
Hull Katherine L.ORCID, Bramham Kate, Brookes Cassandra L., Cluley Victoria, Conefrey Carmel, Cooper Nicola J., Eborall Helen, Fotheringham James, Graham-Brown Matthew P. M., Gray Laura J., Mark Patrick B., Mitra Sandip, Murphy Gavin J., Quann Niamh, Rooshenas Leila, Warren Madeleine, Burton James O.
Abstract
Abstract
Background
In-centre nocturnal haemodialysis (INHD) offers extended-hours haemodialysis, 6 to 8 h thrice-weekly overnight, with the support of dialysis specialist nurses. There is increasing observational data demonstrating potential benefits of INHD on health-related quality of life (HRQoL). There is a lack of randomised controlled trial (RCT) data to confirm these benefits and assess safety.
Methods
The NightLife study is a pragmatic, two-arm, multicentre RCT comparing the impact of 6 months INHD to conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 h per session). The primary outcome is the total score from the Kidney Disease Quality of Life tool at 6 months. Secondary outcomes include sleep and cognitive function, measures of safety, adherence to dialysis and impact on clinical parameters. There is an embedded Process Evaluation to assess implementation, health economic modelling and a QuinteT Recruitment Intervention to understand factors that influence recruitment and retention. Adults (≥ 18 years old) who have been established on haemodialysis for > 3 months are eligible to participate.
Discussion
There are 68,000 adults in the UK that need kidney replacement therapy (KRT), with in-centre haemodialysis the treatment modality for over a third of cases. HRQoL is an independent predictor of hospitalisation and mortality in individuals on maintenance dialysis. Haemodialysis is associated with poor HRQoL in comparison to the general population. INHD has the potential to improve HRQoL. Vigorous RCT evidence of effectiveness is lacking. The NightLife study is an essential step in the understanding of dialysis therapies and will guide patient-centred decisions regarding KRT in the future.
Trial registration
Trial registration number: ISRCTN87042063. Registered: 14/07/2020.
Funder
Health Technology Assessment Programme
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference52 articles.
1. UK Renal Registry. UK renal registry 24th annual report—data to 31/12/2020, Bristol, UK. 2022. Available from https://ukkidney.org/audit-research/annual-report. 2. Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022;18(6):378–95. 3. Mapes DL, Bragg-Gresham JL, Bommer J, Fukuhara S, McKevitt P, Wikström B, et al. Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:54–60. 4. Perl J, Karaboyas A, Morgenstern H, Sen A, Rayner HC, Vanholder RC, et al. Association between changes in quality of life and mortality in hemodialysis patients: results from the DOPPS. Nephrol Dial Transplant. 2017;32(3):521–7. 5. Tentori F, Mapes DL. Opinion: Health-Related Quality of Life and Depression among Participants in the DOPPS: predictors and associations with clinical outcomes. Semin Dial. 2010;23(1):14–6.
|
|